Neotigason (Acitretin)

Acitretin binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression that controls keratinocyte differentiation and proliferation. This results in reduced epidermal hyperplasia, normalization of skin cell turnover, and decreased inflammatory signaling in affected skin.

The dose of Neotigason is individualized by the prescribing clinician based on disease severity, patient weight, and laboratory monitoring. Typical regimens start at a low dose and may be adjusted, but exact dosing must be determined by a qualified healthcare professional.

Neotigason (acitretin) is classified as pregnancy category X because it is highly teratogenic. It must not be used by pregnant women or women planning to become pregnant, and effective contraception is required for at least three years after stopping therapy. Safety during breastfeeding has not been established, and breastfeeding is generally discouraged.

To order Neotigason, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for severe psoriasis includes methotrexate and biologic agents. Compared with methotrexate, acitretin offers a non‑immunosuppressive oral option but carries a higher risk of teratogenicity and lipid abnormalities. Biologics target specific immune pathways and may have faster skin clearance, but they are injectable and often more costly.

Neotigason tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Neotigason is taken orally, usually with a full glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should follow the prescribing physician’s instructions regarding timing and any required dietary considerations.

The most serious risks include teratogenic effects (birth defects), severe liver toxicity, marked hyperlipidemia, depression or mood changes, and rare but serious conditions such as pseudotumor cerebri or severe skin reactions like Stevens‑Johnson syndrome. Regular laboratory monitoring and prompt reporting of symptoms are essential.

Neotigason should not be used by pregnant women, women planning pregnancy, or those who cannot ensure effective contraception for at least three years after stopping therapy. It is also contraindicated in patients with severe hepatic impairment, uncontrolled hyperlipidemia, or a history of severe depression or intracranial hypertension.